UY34896A - Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina - Google Patents

Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina

Info

Publication number
UY34896A
UY34896A UY0001034896A UY34896A UY34896A UY 34896 A UY34896 A UY 34896A UY 0001034896 A UY0001034896 A UY 0001034896A UY 34896 A UY34896 A UY 34896A UY 34896 A UY34896 A UY 34896A
Authority
UY
Uruguay
Prior art keywords
laquinimod
fampridine
treatment
combination
subject
Prior art date
Application number
UY0001034896A
Other languages
English (en)
Inventor
Kaye Joel
Tarcic Nora
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of UY34896A publication Critical patent/UY34896A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Esta invención proporciona 1) un método de tratamiento de un sujeto aquejado de esclerosis múltiple o la presentación de un síndrome clínicamente aislado que comprende administración al sujeto fampr idina como una terapia complementaria a o en comb inación con laquinimod; 2) un paquete o una composición farmacéutica que comprende laquinimod y fam pridina para uso en el tratamiento de dicho sujeto; 3) fampridina para su uso como complemento de la terapia o en combinación con laquinimod en el t ratamiento de dicho sujeto, y 4) uso de laquinimod y fampridina en la preparación de una combinació n para el tratamiento de dicho sujeto
UY0001034896A 2012-07-12 2013-07-09 Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina UY34896A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261670758P 2012-07-12 2012-07-12

Publications (1)

Publication Number Publication Date
UY34896A true UY34896A (es) 2014-02-28

Family

ID=49914160

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034896A UY34896A (es) 2012-07-12 2013-07-09 Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina

Country Status (17)

Country Link
US (2) US20140017226A1 (es)
EP (1) EP2872217A4 (es)
JP (1) JP2015522077A (es)
KR (1) KR20150038072A (es)
CN (1) CN104582793A (es)
AR (1) AR091724A1 (es)
AU (1) AU2013290181A1 (es)
BR (1) BR112015000616A2 (es)
CA (1) CA2873229A1 (es)
EA (1) EA201590191A1 (es)
HK (1) HK1209672A1 (es)
IL (1) IL236230A0 (es)
MX (1) MX2015000485A (es)
PY (1) PY1330684A (es)
TW (1) TW201408300A (es)
UY (1) UY34896A (es)
WO (1) WO2014011827A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106063787A (zh) 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
HK1198296A1 (en) 2012-02-16 2015-03-27 Teva Pharmaceutical Industries Ltd. N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
JP2015535287A (ja) 2012-11-07 2015-12-10 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドのアミン塩
NZ630427A (en) 2013-03-14 2017-06-30 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof
EA201692180A1 (ru) 2014-04-29 2017-08-31 Тева Фармасьютикал Индастриз Лтд. Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации
GB2540163A (en) * 2015-07-07 2017-01-11 Univ London Queen Mary Combination therapy for treating multiple sclerosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726339D0 (en) * 1997-12-13 1998-02-11 Zeneca Ltd Human-derived tissue-specific potassium channel
US20090082471A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
ES2329327B1 (es) * 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.
TW201010703A (en) * 2008-09-10 2010-03-16 Acorda Therapeutics Inc Methods of using sustained release aminopyridine compositions
RS54328B1 (sr) * 2009-06-19 2016-02-29 Teva Pharmaceutical Industries Ltd. Tretman multiple skleroze lakvinimodom
CN106344576A (zh) * 2011-10-12 2017-01-25 泰华制药工业有限公司 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症

Also Published As

Publication number Publication date
BR112015000616A2 (pt) 2017-06-27
US20160235735A1 (en) 2016-08-18
CA2873229A1 (en) 2014-01-16
PY1330684A (es) 2016-06-01
MX2015000485A (es) 2015-04-08
AU2013290181A1 (en) 2015-02-26
KR20150038072A (ko) 2015-04-08
EP2872217A1 (en) 2015-05-20
HK1209672A1 (en) 2016-04-08
WO2014011827A1 (en) 2014-01-16
EP2872217A4 (en) 2016-03-16
CN104582793A (zh) 2015-04-29
EA201590191A1 (ru) 2015-06-30
IL236230A0 (en) 2015-01-29
TW201408300A (zh) 2014-03-01
AR091724A1 (es) 2015-02-25
JP2015522077A (ja) 2015-08-03
US20140017226A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
JOP20120246B1 (ar) مركبات و تركيبات كمثبطات كيناز c-Kit
EA201491773A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата
MX343534B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
IN2014MN00333A (es)
MX2016001037A (es) Inhibidores de factores de transcripción y usos.
MX366899B (es) Nuevos compuestos.
UY34896A (es) Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
MX387235B (es) Derivados de pirazolopiridina y su uso en terapia
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
MX377089B (es) Uso de una proteína angiopoyetina modificada en la preparación de un medicamento para prevenir o tratar la malaria cerebral.
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
HK1218251A1 (zh) 用拉喹莫德治疗多发性硬化症
CO7151509A2 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
IN2013MU02370A (es)
WO2013038200A3 (en) Neurodevelopmental disorders
MX2016001177A (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina.
MX2016003763A (es) Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple.
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
PL397785A1 (pl) Kompozycja i preparat zawierajace tioproline i ergotioneine, zastosowanie tioproliny i ergotioneiny oraz sposób ochrony skóry przed procesem starzenia zewnatrzpochodnego

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210528